The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Interview with Fernando Cruzado, Vice President & Industry Lead Chemicals and Holger Peterkord, Senior Principal & Capex capability lead at Efeso Group

Bruggemann develops reducing agents and recycling additives for sustainable processes and products

In this interview, Charlie Tan, CEO of the Global Impact Coalition (GIC), explains the initiative’s scope and describes some key activities.